ReviewAnnals of translational medicine2024
Exploring the association between pro-inflammatory mediators and sarcopenia in cancer patients through different diagnostic tools: a narrative review.
Review in Annals of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Sarcopenia, characterized by the progressive loss of skeletal muscle mass (MM) and muscle function, is a common and debilitating condition in cancer patients, significantly impacting their quality of life, treatment outcomes, and overall survival. The pathophysiology of sarcopenia is multifactorial, involving metabolic, hormonal, and inflammatory changes. Recent research highlights the role of chronic inflammation in the development and progression of sarcopenia, with pro-inflammatory cytokines being key mediators of muscle catabolism. The primary objective of this study was to assess the role of pro-inflammatory cytokines in identifying sarcopenia among cancer patients. As a secondary objective, we aim to investigate whether the methods used for assessing sarcopenia, both imaging and functional, align with established guidelines. Methods: A search of the Web of Science was conducted for English-language articles published since 2005, with the following terms: "Cancer" AND "Sarcopenia" AND "Pro-inflammatory cytokine*" OR "Interleukin*". Inclusion criteria included peer-reviewed controlled trials, observational studies, case reports, and case series. To avoid redundancy, articles with results which were included in systematic reviews, narrative reviews, or scoping reviews were excluded from this review. Key Content and Findings: The analysis of 10 selected papers, including 1,138 cancer patients, revealed a lack of assessment of muscle strength (MS) and muscle functional performance in most of the studies on sarcopenia, contradicting the comprehensive nature of sarcopenia that includes MM, MS, and muscle functionality. There is no standardization of pro-inflammatory mediators for sarcopenia identification. Conclusions: Future research should focus on establishing cutoff points for inflammatory mediators and identifying which cytokines are linked to sarcopenia. Given the complexity of sarcopenia in different cancers, new projects should investigate whether cytokine expression depends on the tumor type. Moreover, considering that the majority of the study population comprised elderly individuals with primary sarcopenia, it is crucial to discern the extent to which the findings are influenced by age versus cancer-related factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.